research PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort
The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.
Search
for
Sort by
Research
300-330 / 1000+ results 
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research Physical stability and subjective efficacy study of liposome loaded with Clitoria ternatea (butterfly pea) flower extract and Eugenia caryophyllus (clove) oil
Liposomes with butterfly pea extract and clove oil are stable and effective according to users.
research P79: Efficacy of baricitinib in adults with alopecia areata: patients’ perspectives on hair regrowth from two phase III randomized controlled trials (BRAVE‐AA1 and BRAVE‐AA2)
Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.
research 530 A clinical comparison of photobiomodulation devices for the treatment of alopecia in all skin types
More research with diverse participants is needed to determine the effectiveness of photobiomodulation devices for hair loss treatment.
research Comparative Study between The Efficacy and Safety of Topical Immune Therapy with Diphenylcyclopropenone versus Anthralin in The Treatment of Resistant Alopecia Areata
Diphenylcyclopropenone (DPCP) is more effective than anthralin for treating resistant alopecia areata.
research Health-related quality of life in mild-moderate patchy alopecia areata: Results from the first controlled Phase 2 clinical trial in this population with STS01 (dithranol/ProSilic) and challenges for the future
Hair regrowth improved, but quality of life did not.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research ODAC Chairs Reveal Challenges, High Drama in a Decade of Service
ODAC members faced intense pressure but prioritized scientific evidence in drug approval decisions.
research 0475 High-dose UVA-1 therapy improves patient-reported outcomes and clinical scores in patients with sclerosing skin disease
High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.
research Clinical Trial of Finasteride on Alopecia X in a Dog
research Three hundred and eight nanometer excimer light therapy for alopecia universalis that is resistant to other treatments: A clinical study of 11 patients
308-nm excimer light therapy helped over a third of treatment-resistant alopecia universalis patients regrow most of their hair.
research Investigação das atividades alelopática, fitotóxica e antioxidante de extratos e frações de Tridax procumbens L. (Asteraceae). e Ouratea spectabilis (mart. ex engl.) engl. (Ochnaceae)
Tridax procumbens and Ouratea spectabilis can affect other plants' growth and have antioxidant benefits.
research Ultraviolet-Enhanced Trichoscopy—A New Tool to Assess Pili Annulati
UV-enhanced trichoscopy helps diagnose hair shaft disorders like pili annulati.
research Different Symbiotic Species of Armillaria Affect the Yield and Active Compound Contents of Polyporus umbellatus
Using Armillaria strain A541 boosts Polyporus umbellatus yield and polysaccharide content.
research 260 Anti-OX40 monoclonal antibody IMG-007 exhibited clinical activity of hair regrowth, suppressed scalp inflammatory biomarkers in patients with severe alopecia areata in a Ph1b/2a study
IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.
research The Efficacy and Safety of AP-FHG0604T on Female Pattern Hair Loss: A Randomized Double-blind Placebo-controlled Clinical Trial
research Summary of the Preceding Three Alopecia Areata Research Summits: What’s Past Is Prologue
New treatments and strategies are needed for Alopecia Areata, focusing on immune response and better trial designs.
research Sustainable UV approaches supported by greenness and whiteness assessments for estimating a recently FDA-approved combination for managing urologic disorders: Tukey's test
New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.
research The Effect of Umbraulva japonica on the Stimulation of Anagen Phase
Umbraulva japonica extract may help treat hair loss by promoting hair growth phase.
research Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study
Patients with fewer past treatments for alopecia areata respond better to baricitinib.
research 1450 THE TRUE BENEFIT OF PSA-SCREENING: MODELING THE IMPACT OF TRIAL SETTING AND PROTOCOL ON MORTALITY
PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.
research Negative term supplementary protection certificates granted by UK Intellectual Property Office
The UK Intellectual Property Office allows granting of supplementary protection certificates with negative terms.
research A trial of 1% minoxidil used topically for severe alopecia areata.
1% minoxidil didn't improve hair growth for severe alopecia areata.
research Biomarker-based methods for determining noncompliance in a prevention trial
Simple methods using DHT levels effectively assess compliance.
research Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
research Combination Therapy with Cyclosporine and Psoralen Plus Ultraviolet A in the Patients with Severe Alopecia Areata: A Retrospective Study with a Self-Controlled Design
The combination of cyclosporine and PUVA might help treat severe alopecia areata.
research 272 Dupilumab treatment in children with alopecia areata: A real-world, single-center observational study
research Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review
All HPV vaccine studies should be registered and published to reduce reporting bias.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.